BCM
GPCR icon

Bayesian Capital Management’s Structure Therapeutics GPCR Stock Holding History

Bayesian Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,108
Closed -$262K – 892
2024
Q1 		$262K Buy
6,108
+22
+0.4% +$928 0.03% 592
2023
Q4 		$248K Buy
+6,086
New +$349K 0.03% 553

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bayesian Capital Management's GPCR Position: Q2 2024 in Review

Bayesian Capital Management sold out of Structure Therapeutics (GPCR) in Q2 2024, closing a stake of 6,108 shares — an estimated $262K sold.

Bayesian Capital Management first reported a position in GPCR in Q4 2023 and held it in 2 quarters. The position peaked at $262K in Q1 2024. 166 funds tracked by Wall St. Rank hold GPCR as of Q2 2024.

  • Bayesian Capital Management reported no remaining Structure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 6,108 Structure Therapeutics shares in Q2 2024, an estimated $262K.
  • Bayesian Capital Management first reported a position in Structure Therapeutics in Q4 2023 and held it in 2 quarters.
  • Bayesian Capital Management's Structure Therapeutics position peaked at $262K in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.